Great CEOs don't just know how to make their companies more valuable—they know when it's time to move on [Fortune]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Fortune
Take for instance Microsoft CEO and Chairman Satya Nadella, who succeeded Steve Ballmer in 2014, when the company was struggling. Fast forward to today, and Nadella wants the software giant to have the most capable, popular AI models on the market. For a Fortune feature , my colleague Jeremy Khan sat down with the CEO of the tech icon to find out what it's going to take to stay ahead in the AI age. Khan writes: “In 10-plus years as CEO, Nadella has reinvigorated the company, successfully steering it through two technological transformations: from PCs to the era of cloud computing, and now, to the age of AI. Nadella's prescient and early bet on OpenAI and its technology, and the fruitful-if-sometimes-tense relationship that ensued, have given Microsoft as good a shot as any company at supremacy in this new era. The company arguably hasn't been this powerful since it dominated the PC market in the 1990s ‘Wintel' era.” Khan also notes that there's no guarantee Microsoft will retain
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAb Biotherapeutics Rebrands as SAB BIO [Yahoo! Finance]Yahoo! Finance
- SAb Biotherapeutics Rebrands as SAB BIOGlobeNewswire
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
SABS
Earnings
- 5/20/24 - Beat
SABS
Sec Filings
- 5/31/24 - Form 8-K
- 5/30/24 - Form DEF
- 5/21/24 - Form 8-K
- SABS's page on the SEC website